[18F]DASA-23
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for [18F]DASA-23, covering 2024-08-12 to 2024-08-12. Get the full timeline:
Most recent: Clinical Trial Update: [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers [Phase 1]